A Phase 3 Randomized, Double-blind Study Of Pf-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-line Treatment Of Patients With Her2-positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 May 2017
At a glance
- Drugs Trastuzumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 13 Mar 2017 Planned End Date changed from 1 Feb 2018 to 26 Feb 2019.
- 13 Mar 2017 Status changed from suspended to active, no longer recruiting.
- 09 Feb 2017 Status changed from active, no longer recruiting to suspended.